Immunotherapies
Immunotherapies
Therapeutic antibodies like Herceptin and Rituxan rely on effector functions including Antibody Dependent Cellular Cytotoxicity (ADCC) for their efficacy. SeromYx can screen a panel of thousands antibodies to identify a more potent candidate than what exists.
1. DISCOVERY
What function or mix of function correlates with therapeutic efficacy of immunotherapies including monoclonal therapeutic antibodies?
Case Study: Discovery – Guiding monoclonal antibody selection and development
2. LEAD SELECTION
What product construct best delivers the desired mix of function?
Case Study: Selecting a lead from a panel of Fc engineered monoclonal antibodies utilizing functional assays such as Antibody Dependent Cellular Cytotoxicity
3. ASSAY DEVELOPMENT, QUALIFICATION, VALIDATION
Which assays need to be demonstrated to be statistically robust so that data from them can be included in regulatory filings?
Case Study: Coming soon
4. CLINICAL EFFICACY TESTING
Tracking specified functions in clinical trial samples as a surrogate clinical endpoint.
Case Study: Coming soon
5. MANUFACTURING SCALE-UP
Does therapeutic product biophysical and functional quality stay the same during process development?
Case Study: Manufacturing Scale Up
Let's Talk - Contact us today to discuss your project.